30 results about "Nucleotide composition" patented technology

The application discloses application of a rice disease resistance related gene Os04g55720 in bacterial blight breeding and relates to the technical field of modern biotechnology and genetic engineering technology.The rice disease resistance related gene Os04g55720 has a nucleotide sequence as shown in SEQ ID NO.1, is composed of 2821 nucleotides, has a coding region sequence as shown in SEQ ID NO.2, and has a sequence of 2148 nucleotides; the gene encodes a protein with 613 amino acids, and has an amino acid sequence as shown in SEQ ID NO.3.The application proves that overexpression of Os04g55720 enhances the resistance of rice to bacterial blight by means of molecular biology and biochemical technology, and shows that the rice protein OsPGDH-3 can effectively control the incidence of rice bacterial blight at a relatively low level.The application provides a new idea, strategy and gene resource for green prevention and control of rice bacterial blight.

The application discloses a specific nucleic acid aptamer for a heterogeneous core ribonucleoprotein hnRNPA2B1 and application, and belongs to the technical field of nucleic acid aptamer. The hnRNPA2B1 aptamer is a small single-stranded DNA screened from a designed oligonucleotide library through an in-vitro exponential enrichment ligand system evolution (SELEX), is composed of 80 nucleotides, and has high affinity to the target. The hnRNPA2B1 aptamer can be applied in a detection method or a detection product of the hnRNPA2B1 protein, and a targeted regulation drug or a biological preparation, and can be specifically made into a molecular probe, used as a detection reagent, used as a targeted preparation and the like for diagnosis and treatment of diseases related to the hnRNPA2B1 protein. The hnRNPA2B1 aptamer has strong affinity and specificity, has the advantages of low production cost, stability, convenient synthesis and easy modification compared with an antibody, and is a potential substitute for the antibody in disease diagnosis and treatment.

Methods, kits, and oligonucleotides used in the detection of coronavirus, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The nucleotide sequence of the oligonucleotide consists of 300 or less, 150 or less, or 40 or less continuous nucleotides from a nucleotide sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO: 5, or is a variant thereof. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5′ terminus is labeled with a fluorophore and the 3′ terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.

In the present specification, an antisense oligonucleotide or a pharmaceutically acceptable salt thereof, or a hydrate thereof, consisting of 15 to 22 nucleotides complementary to a nucleic acid comprising at least 15 consecutive bases in a target region selected from the group consisting of positions 1 to 102, 159 to 842, 879 to 1822, and 1874 to 4182 from the 5′ end of a base sequence of SEQ ID NO: 1 is provided.

RNA molecules comprising a guide sequence portion having 17-20 nucleotides in the sequence of 17-20 contiguous nucleotides set forth in any one of SEQ ID Nos: 1-1313 and compositions, methods, and uses thereof.

Methods, kits, and oligonucleotides used in the detection of the coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The oligonucleotide consists of 40 or less nucleotides and has a nucleotide sequence that consists essentially of, or is a variant of, the nucleotide sequence of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5′ terminus is labeled with a fluorophore and the 3′ terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.

A method of quantifying RNA capping efficiency, the method comprising: (a) providing a sample of capped RNA; (b) contacting the capped RNA with a nuclease, wherein the nuclease is a protein, thereby hydrolysing the RNA to produce hydrolysis products comprising a capped product comprising dinucleotides, and an uncapped product comprising nucleotides, step (b) being carried out in the absence of a nucleic acid having a base sequence complementary to the sequence of the capped RNA; (c) separating the hydrolysis products by chromatography; and (d) determining the concentrations of the hydrolysis products by triple quadrupole mass spectrometry, thereby quantifying RNA capping efficiency; is provided.

An antitumor agent containing, as an active ingredient, RNA having a base sequence selected from the group consisting of (1) and (2) below, and having at least one nucleotide unit represented by Formula (1) below in a 3′ end region within 20 bases of the 3′ end thereof and / or in a 5′ end region within 25 bases of the 5′ end thereof.(1) A base sequence represented by SEQ ID NO: 2 or a base sequence having 90% or more identity with such sequence(2) A base sequence consisting of between 20 and 200 consecutive nucleotides of the base sequence described in (1) above(In Formula (1), R1 represents a hydroxyl group, a hydroxyl group with a hydrogen atom substituted with an alkyl or alkenyl group, or a halogen atom; R2 represents NHR3 with a linking group, the linking group being a divalent hydrocarbon group with one or more carbon atoms; R3 represents a hydrogen atom, an alkyl group, or an alkenyl group; n is 0 or 1; X1 represents an oxygen atom or sulfur atom; X2 represents OH (or O−) or SH (or S−); and B represents a purine base or a pyrimidine base.)

The present invention provides a tau exon 10 skipping-promoting antisense oligonucleotide containing at least one 2′-O, 4′-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 44 in exon 10 of a tau mRNA precursor. In addition, the present invention provides a tau exon 10 skipping-suppressing antisense oligonucleotide containing at least one 2′-O, 4′-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 45 in intron 10 of a tau mRNA precursor.

Molecular anti-counterfeiting taggants are made from a plurality of synthetic polynucleotides that collectively encode a bit sequence using the sequences and hybridization states of the polynucleotides. The polynucleotide taggant is placed on an item as a molecular identifier of authenticity. The bit sequence encoded by the polynucleotide taggant is read out using a substrate which has bound polynucleotides complexes that hybridize with the synthetic polynucleotides in the polynucleotide taggant. A detectable signal is present where hybridization occurs. To prevent a bad actor from reverse engineering and creating a copy of the polynucleotide taggant using the results of hybridization to the substrate, multiple versions of the substrate are created. Each version hybridizes to different subsets of the synthetic polynucleotides in the polynucleotide taggant. A detectable pattern on the substrate that is present when exposed to the polynucleotide taggant is used for validating authenticity of the item.

Compositions and methods for increasing the solubility and stability of organic nucleotide materials via microencapsulation techniques. A method for making a shelf-stable organic nucleotide compound in a more water-soluble form, the higher-solubility form being provided in liquid and / or powder. The method utilizes a colloidal dispersion solution comprising water, polysaccharides, organic nucleotide and in some cases surfactants. A method for making shelf-stable composition comprising at least one organic nucleotide composition may include combining water, surfactant, polysaccharide, and ATP to form an intermixed colloidal dispersion. The method may include heating the admixed dispersion and running the dispersion under medium shear, wherein the colloidal dispersion provides improved shelf stability to the target nucleotide in water-soluble form.

The present invention relates to: a Cas protein function-regulating switch oligonucleotide, which is an oligonucleotide that hybridizes complementarily to a spacer of a guide RNA and consists of 5 to 20 nucleotides starting from the 5' end; and a target nucleic acid amplification composition comprising same. In addition, the present invention provides the Cas protein function-regulating switch oligonucleotide, which is an oligonucleotide that hybridizes complementarily to a spacer of a guide RNA and consists of 5 to 20 nucleotides starting from the 5' end, thereby regulating the rate at which a Cas protein binds to a target nucleic acid so as to cause an RPA-CRISPR reaction to occur within a single tube without physical separation or additional steps, and thus can be used in a point-of-care diagnostic device.

The application discloses a nucleic acid aptamer PCM-A09 which specifically recognizes procymidone, wherein the nucleotide sequence of the nucleic acid aptamer is shown as SEQ ID NO:1. The nucleic acid aptamer can specifically bind with procymidone. The nucleic acid aptamer PCM-A09 is single-stranded DNA (ssDNA) which is composed of 88 nucleotides. The secondary structure of the nucleic acid aptamer has outstanding stems and loops. The Gibbs free energy DG of the nucleic acid aptamer PCM-A09 is -16.14. The specificity and affinity of the nucleic acid aptamer are evaluated based on colloidal gold spectrophotometry. The experimental results show that the nucleic acid aptamer PCM-A09 can specifically bind with procymidone. The nucleic acid aptamer has the characteristics of high specificity and high affinity. The nucleic acid aptamer can be prepared into a PCM reagent, a detection kit or a sensor and applied to the detection of PCM in various agricultural products.

The invention provides an aptamer capable of specifically recognizing deoxynivalenol and application of the aptamer. The nucleotide sequence of the aptamer is as shown in SEQ ID NO: 1. According to the invention, a key site recognition mechanism of a target molecule is researched by virtue of structural biology, truncation optimization is carried out, the DON aptamer with high affinity, high specificity and high sensitivity is obtained through screening, and the DON aptamer is only composed of 31 nucleotides and has relatively strong anti-interference performance and stability, the cost is remarkably reduced, and the development of an efficient DON detection method is facilitated.

The invention discloses a molecular structure display and interaction system based on a mechanical model and digital interaction, and the system comprises a mechanical model assembly which comprises a rotatable basic group module, a ribose module and a phosphate group module, and is used for the independent combination of a user to form nucleotides; the acquisition module is arranged inside or around the base module, the ribose module and the phosphate group module and is used for detecting the spatial states of the base module, the ribose module and the phosphate group module and acquiring corresponding nucleotide composition information; the identification module is associated with the acquisition module and is configured to receive the nucleotide composition information and identify the nucleotide type formed by the user combination; and the interaction module is associated with the identification module and is used for displaying knowledge content related to the identified nucleotide type and receiving an operation instruction of a user. According to the invention, the problems of lack of interaction content and single experience form of the existing display interaction mode of related abstract microscopic concepts and knowledge contents such as molecular structures and the like can be solved.

The application discloses an immunomodulatory peptide Ha-CATH and application thereof, and belongs to the field of biomedicine. The immunomodulatory peptide Ha-CATH is a cyclic polypeptide with a pair of intramolecular disulfide bonds formed by the eighth cysteine residue and the thirteenth cysteine residue of a skin repair peptide gene of Chinese amphibian Pelophylax nigromaculatus, has a molecular weight of 2361.8 Dalton, an isoelectric point of 6.04, and an amino acid sequence shown in SEQ ID NO:1. A gene (GenBank accession: OQ992774) encoding the precursor of the immunomodulatory peptide Ha-CATH is composed of 714 nucleotides, has a nucleotide sequence shown in SEQ ID NO:2, and the nucleotide sequence of 445-504 is the encoding gene of the immunomodulatory peptide Ha-CATH. ‑ The application also discloses an application of the immunomodulatory peptide Ha-CATH in preparation of a skin wound repair promoting therapeutic drug. ‑ The application also discloses an application of the immunomodulatory peptide Ha-CATH in preparation of a skin wound repair promoting therapeutic drug.

The application belongs to the field of genetic engineering, and discloses a final pythium PuRWP1 gene and application of the gene as a molecular target in disease prevention caused by the final pythium. The application provides a gene PuRWP1 from the final pythium for controlling a sexual development stage and oospore formation. The gene is composed of 1184 nucleotides. A protein coded by the PuRWP1 gene is composed of 627 amino acids. Knockout of the PuRWP1 gene can cause a significant decrease in sporulation capacity and a decrease in spore activity of a mutant. The gene can be used as a molecular target in disease prevention of oomycetes. The application verifies the function of the final pythium PuRWP1 gene, and provides a new direction for further regulating physiological functions of the final pythium and other oomycetes and preventing oomycete diseases by using the gene.

The application belongs to the technical field of genetic engineering, and specifically discloses a gene PoRWP2 for improving the production of Pythium oligandrum oospores and an application thereof. The application analyzes and transforms the Pythium oligandrum PoRWP2 gene, which is composed of 837 nucleotides, and the protein coded by the gene contains 278 amino acids, and can regulate the sexual development and oospore formation process of Pythium oligandrum. The application verifies the function of the PoRWP2 gene, provides a new direction for regulating the physiological function of Pythium oligandrum by using the gene and improving the sporulation capacity of the biocontrol bacteria, and provides a theoretical basis and technical support for developing biocontrol agents based on Pythium oligandrum and carrying out biological control of oomycete diseases.

This application relates to a modified dsRNA molecule and its use. Specifically, this application provides a dsRNA molecule that inhibits the expression of the Lp(a) gene, comprising a sense strand and an antisense strand that complementarily form a double-stranded region, wherein the sense strand and / or the antisense strand contain 15-25 nucleotides or consist of 15-25 nucleotides, and is useful for the treatment and / or prevention of diseases mediated by the Lp(a) gene.

The invention is directed to systems and methods of recording digital information using nucleic acids. A DNA template strand has alpha and beta segments, each with a set of three nucleotides differing from each other. When a DNA polymerase contacts the template in the presence of a first solution of three nucleotides corresponding to an alpha segment, a new strand is extended according to available base pairing. The extension halts when the polymerase encounters a beta strand, as the first solution lacks a base-pairing nucleotide triphosphate. Similarly, when the polymerase is provided with a second solution of three nucleotides corresponding to the beta segment, the new strand continues extension according to available base pairing. As first and second solutions are alternated, chemically-altered nucleotide triphosphates are introduced, providing mutations in certain segments of the new strand. When sequenced, mutation segments are assigned a '1' and non-mutation segments are assigned a 'O'.

The purpose of the present invention is to provide: a double-stranded RNA for inhibiting the expression of both human YAP1 and human WWTR1; and a pharmaceutical composition comprising the same. This double-stranded RNA (dsRNA) for inhibiting the expression of both human YAP1 and human WWTR1 includes a sense strand and an antisense strand. The antisense strand includes a region complementary to a homologous sequence in a human YAP1 transcription product or in a human WWTR1 transcription product. The homologous sequence is a nucleotide sequence formed of 17 nucleotides in the human YAP1 transcription product, or is a nucleotide sequence formed of 17 nucleotides in the human WWTR1 transcription product. When the two nucleotide sequences are aligned, at least 14 nucleotides in consecutive 17 nucleotides are identical. Each of the strands has a length of at least 15 nucleotides. The sense strand and the antisense strand form a double-stranded region.

The present invention provides a method for the preparation of a nucleic acid molecule comprising a sequence of 23 to 80 nucleotides in length capable of binding to a target sequence in a target RNA, the nucleic acid molecule comprising a central base triplet (CBT) (I) of three nucleotides having a central nucleotide (N0) directly opposite a target adenosine in said target RNA. [Formula 1] JPEG2025541721000056.jpg5169 wherein the core oligonucleotide has the following sequence (II): [chemical 2] JPEG2025541721000057.jpg5169 The present disclosure also provides an oligonucleotide and its composition for use in treating or preventing genetic disorders, conditions, or diseases. Also provided is a method for editing a target adenosine or deaminating at least one specific adenosine in a target nucleic acid.

Compositions and methods for improving the solubility and stability of organic nucleotide materials through microencapsulation technology. A method for producing an organic nucleotide compound that is storable at room temperature in a more water-soluble form, wherein the more soluble form is provided in liquid and / or powder form. The method utilizes a colloidal dispersion solution comprising water, polysaccharides, organic nucleotides, and optionally a surfactant. A method for producing a storable composition comprising at least one organic nucleotide composition may involve combining water, a surfactant, polysaccharides, and ATP to form a mixed colloidal dispersion. The method may include heating the mixed dispersion and running the dispersion under moderate shear, wherein the colloidal dispersion provides improved storability for the target nucleotide in its water-soluble form.

The present disclosure relates to a chemically modified oligonucleotide for use in site-directed A-to-I editing of a target RNA inside a cell with endogenous adenosine deaminase acting on RNA (ADAR), the oligonucleotide comprising a sequence capable of binding to a target sequence in a target RNA and a central base triplet (CBT) of 3 nucleotides (5′-N+1 N0 N−1-3′), wherein N0 is the central nucleotide directly opposite to a target adenosine in the target RNA that is to be edited, and wherein the oligonucleotide comprises an asymmetry of 25-1-8 in a 5′ to 3′ direction; and comprises: (i) one or more phosphorothioate (PS) linkages at one or more of position +22, position +21, position +11, and position +4; and / or (ii) a 2′-O-methyl (2′-O-Me) modified nucleosides at position +13 and / or position +9.

Provided are a modified dsRNA molecule and use thereof. Specifically provided is a dsRNA molecule for inhibiting expression of a MASP2 gene, comprising a sense strand and an antisense strand which are complementary to form a double-stranded region, wherein the sense strand and / or the antisense strand comprises or consists of 15-25 nucleotides, and the dsRNA molecule can be used for treating and / or preventing a disease mediated by the MASP2 gene.

  42      Abstract  The present invention is directed to nucleic acid molecules which encode novel luciferases, functional fragments thereof, homologs and mutants, as well as to proteins encoded by said nucleic acids. The nucleic acid molecules of interest are isolated from fungi or obtained by genetic engineering methods. Also, host cells, stable cell lines and transgenic organisms comprising said nucleic acid molecules are provided. In addition, antibodies specific to the proteins of the present invention are provided. Said proteins and nucleic acids are used in many applications and methods, in particular, in labelling organisms, cells, cellular organelles, or proteins. Also, said protein and nucleotide compositions are used in methods for detecting protein-protein interactions, for testing promoter activity under various conditions. Finally, provided are kits for the use of proteins and nucleic acids of the present invention in the diversity of methods and applications. Abstract The present invention is directed to nucleic acid molecules which encode novel luciferases, functional fragments thereof, homologs and mutants, as well as to proteins encoded by said nucleic acids. The nucleic acid molecules of interest are isolated from fungi or obtained by genetic engineering methods. Also, host cells, stable cell lines and transgenic organisms comprising said nucleic acid molecules are provided. In addition, antibodies specific to the proteins of the present invention are provided. Said proteins and nucleic acids are used in many applications and methods, in particular, in labelling organisms, cells, cellular organelles, or proteins. Also, said protein and nucleotide compositions are used in methods for detecting protein-protein interactions, for testing promoter activity under various conditions. Finally, provided are kits for the use of proteins and nucleic acids of the present invention in the diversity of methods and applications. 42 20 24 20 33 78 21 M ay 2 02 4 A b s t r a c t 2 0 2 4 2 0 3 3 7 8 2 1 M a y 2 0 2 4

An oligonucleotide probe for detecting genomic alteration includes a semi-complementary region, a first complementary region, a second complementary region, and a minor groove binder moiety attached to a 3' end of the second complementary region. The semi-complementary region includes nucleotides that are completely complementary to a mutant allele of a portion of a genomic sequence and is not completely complementary to a wild type allele of the portion of the genomic sequence. The first complementary region extends from a 5' end of the semi-complementary region and includes nucleotides that are completely complementary to both the mutant allele and to a wild type allele of the gene. The second complementary region extends from a 3' end of the semi-complementary region and consists of four to seven nucleotides that are completely complementary to both the mutant allele and to the wild type allele.

Novel oligonucleotide-based compounds comprising a (PK) -modifyinganchor are provided.SOLUTION: A compound is provided comprising a first oligonucleotide, wherein the first oligonucleotide comprises at least 16 contiguous nucleotides, a 5 ' terminus, a 3 ' terminus; and a PK modifying anchor comprising an anchor oligonucleotide, an optional linker, and at least one polymer, wherein the anchor oligonucleotide comprises or consists of about 5 to about 15 nucleotides that are complementary to the first oligonucleotide and the polymer is at least about 2, 000Da.SELECTED DRAWING: None

To provide a process for producing a nucleotide composition comprising aggregated oligonucleotides, and a process for producing a composition comprising virus-like particles of an RNA bacteriophage and aggregated oligonucleotides packaged into the virus-like particles.SOLUTION: Provided is a process for producing a nucleotide composition comprising aggregated oligonucleotides, the process comprising the steps of: (a) providing oligonucleotides, wherein the oligonucleotides comprise 3 to 15 guanosine moieties at the 5' end and 3 to 15 guanosine moieties at the 3' end, and comprise phosphodiester-linked deoxynucleotides; (b) denaturing the oligonucleotides by incubating an aqueous solution I comprising the oligonucleotides at 75°C to 99°C until an average diameter of the oligonucleotides becomes 1 nm or less; and (c) aggregating the oligonucleotides.SELECTED DRAWING: None

The application discloses application of a 5'-monophosphate nucleotide composition in preparation of anti-aging and longevity drugs and / or functional foods, and belongs to the technical field of medicines.The composition is composed of 5'-monophosphate adenosine, 5'-monophosphate cytidine, 5'-guanylic acid disodium, 5'-uridylic acid disodium and hypoxanthine nucleotide, and the mass ratio of the acid types of CMP, AMP, UMP, GMP and IMP is respectively as follows: CMP: 15-78%, AMP: 6-44%, UMP: 7-40%, GMP: 7-51%, and IMP is 0 or greater than 0 and not higher than 2.5%. The composition can synergistically enhance various mechanisms such as significantly reducing an insulin resistance index, enhancing body anti-coagulation function, improving blood circulation, regulating metabolism of essential minerals such as lithium and copper and regulating intestinal flora ecology, delays aging and prolongs healthy life span. Animal experiment data show that, compared with a control group, the composition prolongs the median survival time of mice by 9.21-12.6%, and the equivalent human life span is 8.76-12.01 years. Human experiment data show that, compared with the control group, the composition intervention reduces the median age of DNA methylation by 3.08 years, and provides a new idea for developing anti-aging and longevity drugs and / or functional foods.